SOLICITATION NOTICE
66 -- Reagents for Ventana Benchmark Systems
- Notice Date
- 10/2/2014
- Notice Type
- Presolicitation
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02RC42656-85
- Archive Date
- 10/31/2014
- Point of Contact
- Terry Galloway, Phone: 240-276-5384, Seena Ninan, Phone: 240-276-5419
- E-Mail Address
-
gallowaytl@mail.nih.gov, ninans@mail.nih.gov
(gallowaytl@mail.nih.gov, ninans@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E156, Bethesda, MD 20892, UNITED STATES Description National Cancer Institute (NCI), Center for Cancer Research (CCR), Laboratory of Pathology plans to procure on a sole source basis a reagent rental service from Ventana Medical Systems, Inc. a member of the Roche Group, 1910 E. Innovation Park Drive, Tucson, AZ 857655. This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.106-1(b)(2) and 13.501- (a)(1) using simplified acquisition procedures for commercial acquisitions. The North American Industry Classification System code is 325414 and the business size standard is 500 Employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price Indefinite Delivery/ Indefinite Quantity contract. The period of performance of the award will be for five (5) years after the date of award. It has been determined there are no opportunities to acquire green products or services for this procurement. The Laboratory of Pathology has a need to provide immunohistochemical and in situ hybridization assays on formalin-fixed, paraffin embedded and frozen tissue sections from patients enrolled on clinical trials in the NCI and other Institutes. Immunohistochemistry, and in situ hybridization is a widespread and accepted technique used in nearly every diagnostic, surgical pathology laboratory and in research laboratories throughout the world. These assays have become an essential part of cancer diagnosis and have an equally important role in the diagnosis of many infectious diseases. The laboratory currently has four (4) Ventana Medical Systems (VMS) Benchmark XT immunostainers that require proprietary reagents from VMS. The use of the Ventana automated immunostainers has allowed the laboratory to provide a high volume clinical service and offer a full menu of specialized tests. Approximately ¾ of the laboratory's slide volume is run on these systems, and over 150 different antibodies have been validated and optimized on these systems at considerable expense. At the same time, the current automated Benchmark XT systems are approximately seven years old and over that time improvements in the equipment have been made by the company and the XT is being replaced by the Benchmark Ultra. For these reasons, the NCI plans to upgrade the current automated stainers to the next generation Benchmark Ultra systems. These newer models offer a number of advantages, better control over the staining conditions, and the ability to use the machine in single slide mode, rather than in a batch mode allowing continuous initiation of staining as needed. The current Benchmark XTs and the proposed new generation Benchmark Ultras use the same reagents, and would allow a smooth transfer of the clinical workload without any disruptive interruptions for lengthy revalidations. The new systems use the same chemistries and the NCI will be able to seamlessly export current standard operating procedures to the upgraded Benchmark Ultra systems. The NCI has developed and optimized standard operating procedures (SOPs) for over 150 antibodies on the Benchmark systems. Conversion to another platform would be difficult, costly, and inefficient. The development of standard operating procedures and interpretations of staining requires extensive validation and accumulated experience with particular reagents and the particular staining platform being used. Conversion to a new platform would be both an enormous undertaking, both a burden to the technicians and pathologists, and not in the interest of NIH patients. Ventana Medical Systems shall upgrade the Government owned Benchmark XTs to the new generation Benchmark Ultras in exchange for purchase of the reagents and supplies that are needed to operate the systems, and can only be purchased from Ventana Medical Systems. The reagents and materials shall be used primarily to support the clinical mission of the Laboratory of Pathology, NCI, and secondarily to support its research mission. This notice is not a request for competitive quotation. However, if any interested party, especially small business believes it can meet the above requirement, it may submit a proposal or quote for the Government to consider. The response and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 11 AM EST, on October 17, 2014. All responses and questions must be in writing and faxed to 240-276-5401 or emailed to Terry Galloway, Contracting Officer via electronic mail at terry.galloway@nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA) through sam.gov. Reference: N02RC42656-85 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02RC42656-85/listing.html)
- Record
- SN03541694-W 20141004/141002235527-ef5bbee19a3e5e9ba2a3ed2565deee38 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |